To be administered by subcutaneous (SC) or intravenous (IV) route only.
Do not administer rhG-CSF injection in the period 24 hours before through 24 hours after the administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to these agents.
RhG-CSF should NOT be diluted with saline solutions as the product may precipitate.
Inspect parenteral solutions visually for particulate matter and discoloration prior to use. Do not use if particulates or discoloration are observed.
Dosage and administration time of rhG-CSF injection are decided according to intensity of chemotherapy and declining degree of neutrophilic granulocytes as follows: See table.
Click on icon to see table/diagram/image
Laboratory monitoring: Obtain a complete blood count (CBC) and platelet count before instituting rhG-CSF therapy. Monitor these parameters two times a week during therapy.
Discontinue rhG-CSF if the ANC exceeds 10 x 109/L after the expected chemotherapy-induced neutropenia.